Influenza A virus H1N1 vaccine - CEL-SCI

Drug Profile

Influenza A virus H1N1 vaccine - CEL-SCI

Alternative Names: L.E.A.P.S. swine flu vaccine - CEL-SCI; LEAPS-H1N1; LEAPS-H1N1-DC

Latest Information Update: 18 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CEL-SCI Corporation
  • Developer CEL-SCI Corporation; Johns Hopkins University
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H1N1 subtype

Most Recent Events

  • 08 Jun 2018 CEL-SCI has patent protection for LEAPS technology in USA
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype(Prevention) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top